The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
Acquisition expands Merck’s growing hematology portfolio
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company is focussed on increasing the capacity utilizations while controlling costs
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Subscribe To Our Newsletter & Stay Updated
